Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients

[Guest guest]

http://www3.interscience.wiley.com/journal/123308907/abstract

Journal of Viral Hepatitis

Volume 17 Issue s1, Pages 59 - 65

Special Issue: Conquering Hepatitis B: Experience from China

Published Online: 3 Mar 2010

© 2010 Blackwell Publishing Ltd

Virological response to antiviral therapy at week 12 indicates a great reduction

of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic

hepatitis B patients

H. Y. Lu 1 , L. W. Zhuang 2 , Y. Y. Yu 1 and C. W. Si 1

1 Department of Infectious Disease, Peking University First Hospital ; and 2

Bejing Ditan Hospital, Beijing, China

Correspondence to Professor Yan-Yan Yu, MD, Department of Infectious Disease,

Peking University First Hospital, 8 Xishiku Street, Beijing 100034, China.

E-mail: yyy@...

Copyright © 2010 Blackwell Publishing Ltd

ABSTRACT

Summary. Early virological response is considered to be a predictor for the

outcome of anti-hepatitis B virus (HBV) therapy. To analyze its correlation to

intrahepatic HBV DNA and covalently closed circular DNA (ccc)DNA, 71 hepatitis B

virus e antigen (HBeAg)-positive chronic hepatitis B patients were recruited: 34

patients were treated with lamivudine; 13 with interferon-α2b; and 24 with

sequential therapy of lamivudine–interferon-α2b for 48 weeks. Intrahepatic

HBV DNA and cccDNA load were measured at the baseline and at Week 48.

Fifty-seven patients had virological response at Week 12. Median decreases of

serum HBV DNA in patients with or without virological response at Week 12 were

4.0 log10 (max. 6.2, min. 2.2) and 1.1 log10 (max. 2.1, min. 0) (Z = −5.766, P

= 0.0000), respectively. At Week 48 they were 4.1 log10 (max. 7.4, min. 1.0) and

2.3 log10 (max. 7.5, min. 0.3) (Z = −2.760, P = 0.006), respectively. For

intrahepatic HBV DNA load they were 1.3 log10 (max. 4.3, min. −1.2) and 0.6

log10 (max. 3.5, min. −0.8), respectively, and for HBV cccDNA load they were

1.1 log10 (max. 4.8, min. −0.5) and 0.5 log10 (max. 3.0, min. −0.8) (Z =

−2.097, P = 0.036), respectively at Week 48. Step-wise logistic regression

analysis indicated that the baseline intrahepatic HBV DNA load effected

virological response at Week 12 [odds ratio (OR) 0.405; 95% confidence interval

(CI) 0.174–0.944; P = 0.036] and HBeAg seroconversion at Week 48 (OR 0.292;

95% CI 0.131–0.649; P = 0.003). In conclusion, virological response at Week 12

indicated a great reduction of intrahepatic DNA and cccDNA load in

HBeAg-positive CHB patients. The baseline intrahepatic HBV DNA load affected

virological response at Week 12 and HBeAg seroconversion at Week 48.

--------------------------------------------------------------------------------

Received June 2009; accepted for publication September 2009

DIGITAL OBJECT IDENTIFIER (DOI)

10.1111/j.1365-2893.2010.01272

[Guest guest]

http://www3.interscience.wiley.com/journal/123308907/abstract

Journal of Viral Hepatitis

Volume 17 Issue s1, Pages 59 - 65

Special Issue: Conquering Hepatitis B: Experience from China

Published Online: 3 Mar 2010

© 2010 Blackwell Publishing Ltd

Virological response to antiviral therapy at week 12 indicates a great reduction

of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic

hepatitis B patients

H. Y. Lu 1 , L. W. Zhuang 2 , Y. Y. Yu 1 and C. W. Si 1

1 Department of Infectious Disease, Peking University First Hospital ; and 2

Bejing Ditan Hospital, Beijing, China

Correspondence to Professor Yan-Yan Yu, MD, Department of Infectious Disease,

Peking University First Hospital, 8 Xishiku Street, Beijing 100034, China.

E-mail: yyy@...

Copyright © 2010 Blackwell Publishing Ltd

ABSTRACT

Summary. Early virological response is considered to be a predictor for the

outcome of anti-hepatitis B virus (HBV) therapy. To analyze its correlation to

intrahepatic HBV DNA and covalently closed circular DNA (ccc)DNA, 71 hepatitis B

virus e antigen (HBeAg)-positive chronic hepatitis B patients were recruited: 34

patients were treated with lamivudine; 13 with interferon-α2b; and 24 with

sequential therapy of lamivudine–interferon-α2b for 48 weeks. Intrahepatic

HBV DNA and cccDNA load were measured at the baseline and at Week 48.

Fifty-seven patients had virological response at Week 12. Median decreases of

serum HBV DNA in patients with or without virological response at Week 12 were

4.0 log10 (max. 6.2, min. 2.2) and 1.1 log10 (max. 2.1, min. 0) (Z = −5.766, P

= 0.0000), respectively. At Week 48 they were 4.1 log10 (max. 7.4, min. 1.0) and

2.3 log10 (max. 7.5, min. 0.3) (Z = −2.760, P = 0.006), respectively. For

intrahepatic HBV DNA load they were 1.3 log10 (max. 4.3, min. −1.2) and 0.6

log10 (max. 3.5, min. −0.8), respectively, and for HBV cccDNA load they were

1.1 log10 (max. 4.8, min. −0.5) and 0.5 log10 (max. 3.0, min. −0.8) (Z =

−2.097, P = 0.036), respectively at Week 48. Step-wise logistic regression

analysis indicated that the baseline intrahepatic HBV DNA load effected

virological response at Week 12 [odds ratio (OR) 0.405; 95% confidence interval

(CI) 0.174–0.944; P = 0.036] and HBeAg seroconversion at Week 48 (OR 0.292;

95% CI 0.131–0.649; P = 0.003). In conclusion, virological response at Week 12

indicated a great reduction of intrahepatic DNA and cccDNA load in

HBeAg-positive CHB patients. The baseline intrahepatic HBV DNA load affected

virological response at Week 12 and HBeAg seroconversion at Week 48.

--------------------------------------------------------------------------------

Received June 2009; accepted for publication September 2009

DIGITAL OBJECT IDENTIFIER (DOI)

10.1111/j.1365-2893.2010.01272